EUVIMEDEUVIMED entdecken
Crossref

Discovery of the tryptanthrin‐derived indoloquinazoline as an anti‐breast cancer agent via ERK / JNK activation

Chih-Shiang Chang, Li-Yuan Bai, Chang-Fang Chiu, Jing-Lan Hu, Jing-Ru Weng iD

Environmental Toxicology · 2024

DOI: 10.1002/tox.24226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Environmental Toxicology, 2024. Verfasst von Chih-Shiang Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Apoptosis, Breast Neoplasms, Cell Survival. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: China Medical University Hospital, Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence, National Health Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tryptanthrin, an alkaloid applied in traditional Chinese medicine, exhibits a variety of pharmacological activities. This study aimed to investigate the anti‐tumor activity of the tryptanthrin derivative (8‐cyanoindolo[2,1‐ b ]quinazoline‐6,12‐dione [CIQ]) in breast cancer cells. In both MDA‐MB‐231 and MCF‐7 breast cancer cells, CIQ inhibited cell viability and promoted caspase‐dependent apoptosis. At the concentration‐ and time‐dependent ways, CIQ increased the levels of p‐ERK, p‐JNK, and p‐p38 in breast cancer cells. We found that exposure to the JNK inhibitor or the ERK inhibitor partially reversed CIQ's viability. We also observed that CIQ increased reactive oxygen species (ROS) generation, and upregulated the phosphorylation and expression of H2AX. However, the pretreatment of the antioxidants did not protect the cells against CIQ's effects on cell viability and apoptosis, which suggested that ROS does not play a major role in the mechanism of action of CIQ. In addition, CIQ inhibited the invasion of MDA‐MB‐231 cells and decreased the expression of the prometastatic factors (MMP‐2 and Snail). These findings demonstrated that the possibility of this compound to show promise in playing an important role against breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsApoptosisBreast NeoplasmsCell SurvivalQuinazolinesFemaleHumansCell Line, TumorMAP Kinase Signaling SystemMCF-7 CellsReactive Oxygen Species

Stichwörter der Autor:innen

ERKJNKROSbreast cancerinvasiontryptanthrin

Substanzen

Antineoplastic AgentsQuinazolinesReactive Oxygen Species

Autor:innen und Institutionen

  • School of Pharmacy, China Medical University, Taichung, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
  • College of Medicine, China Medical University, Taichung, Taiwan.
  • Cancer Center, China Medical University Hospital, Taichung, Taiwan.
  • Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung, Taiwan.
  • Master Degree Program in Toxicology, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Jing-Ru Weng

Förderung

  • China Medical University Hospital
  • Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence
  • National Health Research Institutes
  • Ministry of Science and Technology

Zitieren

APA

Chang, C. S., Bai, L. Y., Chiu, C. F., Hu, J. L., & Weng, J. R. (2024). Discovery of the tryptanthrin‐derived indoloquinazoline as an anti‐breast cancer agent via ERK / JNK activation. Environmental Toxicology. https://doi.org/10.1002/tox.24226

Vancouver

Chang CS, Bai LY, Chiu CF, Hu JL, Weng JR. Discovery of the tryptanthrin‐derived indoloquinazoline as an anti‐breast cancer agent via ERK / JNK activation. Environmental Toxicology. 2024. doi:10.1002/tox.24226

BibTeX
@article{Chang2024,
  author = {Chang, Chih-Shiang and Bai, Li-Yuan and Chiu, Chang-Fang and Hu, Jing-Lan and Weng, Jing-Ru},
  title = {Discovery of the tryptanthrin‐derived indoloquinazoline as an anti‐breast cancer agent via ERK / JNK activation},
  journal = {Environmental Toxicology},
  year = {2024},
  doi = {10.1002/tox.24226}
}
Kostenlos starten →